Results 81 to 90 of about 1,233,301 (210)

Successful Percutaneous Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation in a High-risk Patient with Cardiorenal Syndrome

US Cardiology Review
The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment of severe aortic regurgitation (AR) presents a challenge for high-risk patients. In this report, we describe the successful treatment of an 84-year-old
Deniz Mutlu, Ibrahim Halil Inanc, Ozgecan Piril Zanbak Mutlu, Konstantinos Marmagkiolis, Cezar A Iliescu, Mehmet Cilingiroglu   +5 more
doaj   +1 more source

The cardiorenal problem

Swiss Medical Weekly, 2014
Cardiorenal syndrome (CRS) describes the reciprocally detrimental interaction between both acute and chronic cardiac and renal dysfunction. The syndrome is prevalent and carries a high mortality.
Emiliy Pollock, Albina Nowak
doaj   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

Cardiorenal syndrome

Canadian Medical Association Journal, 2023
Ye, Wen Qing Wendy, Qureshi, Mohammad Azfar, Auguste, Bourne   +2 more
openaire   +2 more sources

Imaging of the cardiorenal syndrome and visceral fat [PDF]

, 2022
This thesis shows the potential utility of imaging biomarkers of the heart, kidneys, and visceral adiposity in the clinical management of cardiorenal syndrome and type 2 diabetes.
Lin, L.
core  

Cardiorenal and hepatorenal syndrome

Journal of Pediatric Critical Care, 2018
Cardiorenal syndrome(CRS) is an interdependent involvement of the heart and the kidney that leads to high morbidity, recurrent readmissions and grave prognosis.
Anand Bhutada, Abhijit Choudhary, Atul Kapse, Vinayak Patki   +3 more
doaj   +1 more source

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aim Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with FD. Methods We conducted
Leandra Serio, Michele Rossi, Amir Askarinejad, Enrico Tartaglia, Tommaso Bucci, Enrica Marrone, Dinesh K. Kalra, Claudio Ferri, Gregory Y. H. Lip   +8 more
wiley   +1 more source

GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To critically examine the evolving evidence on glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and the dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonist tirzepatide as adjuncts to insulin therapy in type 1 diabetes (T1D), with particular emphasis on their benefit–risk balance in individuals with ...
Thales Rossatto, Ricardo de Andrade Oliveira, Andréia Machado Cardoso   +2 more
wiley   +1 more source

Cardiorenal Syndrome, Hemodynamics, and Noninvasive Evaluation

, 2017
Cardiorenal syndrome is a group of disorders resulting from the pathological interaction between the heart and the kidneys. The most accepted classification of cardiorenal syndrome differentiates the types based on the temporal sequence of organ ...
Ibrahim, Michel, Gabriel A Hernandez, Hernandez, Gabriel A., Cabeza, Franco, Camilo Cortesi, Michel Ibrahim, Franco Cabeza Rivera, Cortesi, Camilo, Rivera, Franco Cabeza   +8 more
core   +1 more source